ATG induction therapy and the incidence of bronchiolitis obliterans after lung transplantation: does it make a difference?
Wiebe
K
K
Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, Germany.
Harringer
W
W
Wahlers
T
T
Franke
U
U
Strüber
M
M
Hamm
M
M
Cremer
J
J
Haverich
A
A
D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D001989:Bronchiolitis Obliterans / Q000453:epidemiology* / Q000473:pathology / Q000517:prevention & control; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D016041:Heart-Lung Transplantation / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D016040:Lung Transplantation / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D011183:Postoperative Complications; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents